A venture capital firm with its newest fund closed in 2020, focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.
The firm invests in therapeutics. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.
The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply